Pharmacologic suppression of JAK2 could diminish graft-versus-host disease and retain the graft-versus-leukemia effect in allogeneic hematopoietic stem cell transplantation, and was thus suggested to be applied in diseases including organ transplant rejection [21]. Here, JAK2 is linked to leukemia.